ASH: Sickle Cell Treatment Decisions In The Post-Oxbryta, Genetic Medicine Era
Patients Have One Less Option Than A Year Ago
Hematologists discussed the still limited treatment options for sickle cell disease at ASH, weighing the risks and benefits of disease-modifying versus curative therapies after the withdrawal of Pfizer’s Oxbryta (voxelotor).
